眼科疾病治療市場規模、佔有率和成長分析：按疾病、藥物分類和地區分類－2026-2033年產業預測

2024 年眼科疾病治療市場價值為 355.4 億美元，預計到 2033 年將成長至 605.6 億美元，而 2025 年為 377.1 億美元，預測期（2026-2033 年）的複合年成長率為 6.1%。

受全球眼科疾病率上升以及由此產生的對有效視力保健解決方案的需求推動，眼科疾病治療市場正經歷強勁成長。視力喪失帶來的經濟影響巨大，凸顯了標靶治療方法的迫切需求。各大製藥公司正大力投資研發視網膜疾病的創新治療方法，預計一系列新治療方法的推出將進一步增強市場動態。此外，亞洲市場非處方藥價格親民的出現可望擴大該領域的收入來源。在各類治療藥物中，抗發炎藥物目前佔據市場主導地位，擁有較大的市場佔有率，並有望在未來繼續保持其在眼科疾病治療領域的領先地位。

眼科疾病治療市場成長要素

眼科治療市場主要受艾爾建公司（Allergan plc）、羅氏公司（F. Hoffmann-La Roche AG）和再生元製藥公司（Regeneron Pharmaceuticals, Inc.）等大型企業的影響。由於越來越多的中小型區域性公司進入市場，競爭格局高度分散。供應商的多樣性促進了創新，並拓寬了患者的治療選擇，從而推動了該行業的成長。老字型大小企業企業與新興企業的共存創造了一個充滿活力的環境，促使眼科治療方案不斷進步，最終造福於需要有效治療的患者。

影響眼科疾病治療市場發展的因素

眼科藥物市場的成長面臨諸多挑戰，其中眼科藥物研發過程中耗時較長的生產和配方流程尤為突出。這一漫長的過程會阻礙企業有效率地將產品推向市場。此外，這些藥物潛在的副作用也會使患者和醫療專業人員望而卻步，進一步限制了市場擴張。因此，這些因素限制著整個眼科藥物產業的發展，使得創新和流程最佳化成為產業相關人員克服這些障礙的關鍵。

眼科疾病治療藥物市場趨勢

眼科治療市場正經歷顯著的發展趨勢，這主要得益於眼科領域的快速技術進步。先進的影像技術和尖端的手術器械等創新技術正在改善眼科疾病的診斷和治療。飛秒雷射在白內障手術中的應用便是這一趨勢的典型例證，它不僅提高了手術的精準度，還最大限度地降低了併發症的風險。此外，微創手術和數位化醫療解決方案的發展正在變革患者照護，而人工智慧（AI）也被用於提高診斷的準確性。隨著研究的深入，這些技術可望提升治療效果，並徹底改變眼科醫學。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 價格分析
• 案例研究
• 技術分析
• 專利分析

全球眼科疾病治療市場規模：依治療方法分類

• 抗 VEGF 療法
• 抗發炎藥
• 青光眼治療藥物
• 抗感染藥物
• 其他

全球眼科疾病治療市場規模：依疾病類型分類

• 老齡化黃斑部病變（AMD）
• 青光眼
• 乾眼症
• 糖尿病視網膜病變
• 眼部感染疾病
• 其他

全球眼科疾病治療市場規模：依給藥途徑分類

• 局部的
• 口服
• 注射藥物
• 其他

全球眼科治療藥物市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

全球眼科疾病治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• AbbVie Inc.
• Regeneron Pharmaceuticals, Inc.
• Bayer AG
• Pfizer Inc.
• Sanofi SA
• Johnson & Johnson
• Alcon Inc.
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co., Ltd.
• Otsuka Holdings Co., Ltd.
• Astellas Pharma Inc.
• GlaxoSmithKline plc
• Amgen Inc.
• EyePoint Pharmaceuticals, Inc.
• Genentech, Inc.
• Apellis Pharmaceuticals, Inc.
• Kowa Company, Ltd.
• Nidek Co., Ltd.

結論與建議

Ophthalmic Disease Therapeutics Market size was valued at USD 35.54 Billion in 2024 and is poised to grow from USD 37.71 Billion in 2025 to USD 60.56 Billion by 2033, growing at a CAGR of 6.1% during the forecast period (2026-2033).

The ophthalmic disease therapeutics market is witnessing robust growth, driven by the rising global incidence of ocular diseases and the consequent need for effective vision care solutions. The economic impact of vision loss is significant, underscoring the urgency for targeted treatments. Major pharmaceutical companies are heavily investing in the development of innovative therapies aimed at retinal disorders, foreshadowing a wave of new treatment options that will further elevate market dynamics. Additionally, the rise of affordable over-the-counter medications in Asian markets is expected to enhance revenue streams within the sector. Among various therapeutic classes, anti-inflammatory medications currently lead the market, holding a substantial share and poised to sustain their dominance in the future landscape of ophthalmic disease treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Ophthalmic Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Ophthalmic Disease Therapeutics Market Segments Analysis

Global Ophthalmic Disease Therapeutics Market is segmented by Drug Class, Dosage Form, Disease Indication, Distribution Channel and region. Based on Drug Class, the market is segmented into anti-inflammatory, anti-infectives, Anti-VEGF, anti-glaucoma and others. Based on Dosage Form, the market is segmented into solid, liquid and semisolid. Based on Disease Indication, the market is segmented into glaucoma, dry eye disease, retinal diseases, allergy & infections and others. Based on Distribution Channel, the market is segmented into hospital pharmacies and retail & online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Ophthalmic Disease Therapeutics Market

The ophthalmic disease therapeutics market is significantly influenced by prominent players such as Allergan plc, F. Hoffmann-La Roche AG, and Regeneron Pharmaceuticals, Inc. The competitive landscape is characterized by a high degree of fragmentation, driven by an increasing number of small to mid-sized regional companies entering the market. This diversity among vendors enhances innovation and expands treatment options available to patients, thereby fostering growth within the sector. The presence of established firms alongside emerging players contributes to a dynamic environment where advancements in therapeutic solutions for ophthalmic diseases are continually being pursued, ultimately benefiting those in need of effective treatments.

Restraints in the Ophthalmic Disease Therapeutics Market

The growth of the ophthalmic disease therapeutics market faces significant challenges due to the lengthy manufacturing and formulation processes involved in developing ophthalmic drugs. These extended timelines can hinder the ability of companies to bring products to market efficiently. Additionally, the potential side effects associated with these medications may deter patients and healthcare providers from utilizing them, further limiting market expansion. As a result, these factors contribute to the overall constraints on the ophthalmic therapeutics sector, making it essential for industry players to innovate and streamline processes to overcome these hurdles.

Market Trends of the Ophthalmic Disease Therapeutics Market

The Ophthalmic Disease Therapeutics market is experiencing a significant trend driven by rapid technological advancements in the field of ophthalmology. Innovations such as advanced imaging techniques and state-of-the-art surgical tools are enhancing the diagnosis and treatment of eye diseases. The integration of femtosecond lasers in cataract surgeries epitomizes this trend, providing greater precision and minimizing the risk of complications. Additionally, the development of minimally invasive procedures and digital health solutions is transforming patient care, while artificial intelligence is being leveraged for improved diagnostics. As research progresses, these technologies are expected to bolster therapeutic outcomes and reshape ophthalmic care.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Technology Analysis
• Patent Analysis

Global Ophthalmic Disease Therapeutics Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Anti-VEGF Therapy
• Anti-Inflammatory Drugs
• Anti-Glaucoma Drugs
• Anti-Infective Drugs
• Others

Global Ophthalmic Disease Therapeutics Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Age-Related Macular Degeneration (AMD)
• Glaucoma
• Dry Eye Disease
• Diabetic Retinopathy
• Ocular Infections
• Others

Global Ophthalmic Disease Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Topical
• Oral
• Injectable
• Others

Global Ophthalmic Disease Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Ophthalmic Disease Therapeutics Market Size & CAGR (2026-2033)

• North America (Therapy Type, Disease Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Therapy Type, Disease Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Disease Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Disease Type, Route of Administration, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Disease Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apellis Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kowa Company, Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nidek Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations